Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
PBYI
#3129
PUMA BIOTECHNOLOGY INC
7.6
2
USD
+0.66%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+0.66%
Changement Mensuel
+27.00%
Evolution sur 6 mois
+37.30%
Changement Annuel
+159.18%
Clôture Précédente
7.5
7
Open
7.5
6
Bid
Ask
Low
7.5
6
High
7.6
2
Volume
27
Marchés
Actions des Marchés US
Soins de Santé
PBYI
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
40.26 M
41.33 M
46.64 M
48.21 M
49.61 M
50.88 M
—
Valuation ratios
Enterprise value
426.07 M
159.61 M
214.73 M
233.21 M
149.14 M
295.6 M
846.22 M
Price to earnings ratio
—
—
—
10.06
4.92
9.75
24.09
Price to sales ratio
—
—
0.81
0.91
0.65
1.32
3.91
Price to cash flow ratio
—
—
-11.72
7.97
3.85
7.21
21.86
Price to book ratio
—
—
8.59
4.03
1.63
2.31
3.9
Enterprise value to EBITDA ratio
-20.49
14.23
6.88
4.79
2.7
5.89
14.18
Profitability ratios
Return on assets %
-0.25
-0.13
0
0.09
0.14
0.14
0.15
Return on equity %
10.08
11.91
0
0.4
0.33
0.24
0.27
Return on invested capital %
-116.14
4.51
0.4
104.46
128.94
130.27
131.57
Gross margin %
100
74.84
75.84
73.4
72.06
74.53
300.6
Operating margin %
-13.51
0.51
10.4
13.85
13.44
16.33
61.56
EBITDA margin %
-9.42
4.97
14.7
18.69
17.82
20.76
89.34
Net margin %
-26.65
-11.51
0
9.16
13.14
13.62
51.67
Liquidity ratios
Quick ratio
1.25
1.21
1.67
1.5
1.45
1.93
6.6
Current ratio
1.28
1.28
1.73
1.57
1.54
2
6.99
Inventory turnover
—
12.06
9.47
10.8
8.15
8.17
7.06
Asset turnover
0.94
1.08
1.02
1.04
1.04
1.06
1.13
Solvency ratios
Debt to assets ratio
0.4
0.43
0.44
0.43
0.31
0.1
0.79
Debt to equity ratio
-16.52
-39.69
4.55
1.86
0.73
0.17
1.47
Long term debt to total assets ratio
0.34
0.43
0.44
0.28
0.1
0
0.11
Long term debt to total equity ratio
-14.12
-39.69
4.55
1.23
0.24
0
0.21
Per share metrics
Operating cash flow per share
—
—
-0.35
0.57
0.79
0.83
0.83
EBIT per share
—
—
0.53
0.69
0.63
0.74
0.74
EBITDA per share
—
—
0.75
0.93
0.84
0.94
1.08
Total debt per share
—
—
2.19
2.1
1.37
0.44
3.12
Cash per share
—
—
1.04
1.03
1.77
1.81
6.96
Net current asset value per share
—
—
2.99
3.28
3.01
3.21
11.41
Tangible book value per share
—
—
-1.09
-0.16
0.83
1.76
5.29
Working capital per share
—
—
1.26
1.19
1.05
1.61
4.87
Book value per share
—
—
0.48
1.12
1.88
2.57
8.87
Puma Biotechnology Inc
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
Nouvelles
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
Puma Biotechnology T4 2025 : chiffre d’affaires NERLYNX en hausse de 15%
Puma Biotechnology présente de solides résultats pour le T4 2025
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
Puma Biotech à la conférence TD Cowen : croissance stratégique
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
Puma Biotechnology, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-02-27
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
Le BPA de Puma Biotech a dépassé les attentes de 0,02$, le CA a surpassé les prévisions
Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates